N
Netanya S. Utay
Researcher at University of Texas Health Science Center at Houston
Publications - 43
Citations - 1177
Netanya S. Utay is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Fibrosis & Medicine. The author has an hindex of 13, co-authored 39 publications receiving 916 citations. Previous affiliations of Netanya S. Utay include University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption
Meghan K Rothenberger,Brandon F. Keele,Stephen W. Wietgrefe,Courtney V. Fletcher,Gregory J. Beilman,Jeffrey G. Chipman,Alexander Khoruts,Jacob D. Estes,Jodi Anderson,Samuel P. Callisto,Thomas E. Schmidt,Ann Thorkelson,Cavan S. Reilly,Katherine Perkey,Thomas Reimann,Netanya S. Utay,Krystelle Nganou Makamdop,Mario Stevenson,Daniel C. Douek,Ashley T. Haase,Timothy W. Schacker +20 more
TL;DR: Recrudescent infection was detectable in multiple different LTs, and the population was genetically diverse, consistent with reactivation from a larger number of cells, underscore the challenges facing strategies to eradicate HIV infection.
Journal ArticleDOI
Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
Irini Sereti,Shelly J. Krebs,Nittaya Phanuphak,James L. K. Fletcher,Bonnie M. Slike,Suteeraporn Pinyakorn,Robert J. O'Connell,Adam Rupert,Nicolas Chomont,Victor Valcour,Jerome H. Kim,Merlin L. Robb,Nelson L. Michael,Daniel C. Douek,Jintanat Ananworanich,Jintanat Ananworanich,Netanya S. Utay +16 more
TL;DR: ART initiated in early acute HIV infection was associated with normalization of the coagulation cascade and several systemic inflammatory biomarkers, but the acute-phase response, enterocyte turnover, monocyte activation, and fibrosis biomarkers remained elevated.
Journal ArticleDOI
Initiation of antiretroviral therapy in early HIV infection reduces but does not abrogate chronic residual inflammation
Irini Sereti,Shelly J. Krebs,Shelly J. Krebs,Nittaya Phanuphak,James L. K. Fletcher,Bonnie M. Slike,Bonnie M. Slike,Suteeraporn Pinyakorn,Suteeraporn Pinyakorn,Robert J. O'Connell,Robert J. O'Connell,Robert J. O'Connell,Adam Rupert,Nicolas Chomont,Victor Valcour,Jerome Kim,Jerome Kim,Jerome Kim,Merlin L. Robb,Merlin L. Robb,Nelson L. Michael,Nelson L. Michael,Daniel C. Douek,Jintanat Ananworanich,Jintanat Ananworanich,Netanya S. Utay +25 more
Journal ArticleDOI
Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy
TL;DR: The history of HIV, type I interferons, IFN-I’s sources, IFn-I's effects on HIV control and host defense, and recent interventional studies in SIV and HIV infection are described.
Journal ArticleDOI
Interferons and HIV Infection: The Good, the Bad, and the Ugly
Netanya S. Utay,Daniel C. Douek +1 more
TL;DR: Whether the effect of type I IFN signaling on HIV disease is good, bad, or so complicated as to be ugly remains a topic of hot debate.